Targeted radiation zaps advanced prostate cancer in new trial

NCT ID NCT05413850

Summary

This study is testing a new radioactive drug called lutetium (177Lu) rhPSMA-10.1 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The goal is to find a safe and effective dose that can shrink tumors by delivering radiation directly to cancer cells. The study will involve about 82 men whose cancer has progressed after prior treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beatson West of Scotland Cancer Center

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Biogenix Molecular LLC

    RECRUITING

    Miami, Florida, 33165, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Bristol Hematology and Oncology Center

    RECRUITING

    Bristol, BS2 8ED, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Rechts der Isar

    RECRUITING

    Munich, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • James Cook University Hospital

    RECRUITING

    Middlesbrough, TS4 3BW, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jules Bordet Institute

    WITHDRAWN

    Brussels, 1000, Belgium

  • Meander Medisch Centrum

    RECRUITING

    Amersfoort, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Radboud UMC

    RECRUITING

    Nijmegen, Gelderland, 6525GA, Netherlands

    Contact Email: •••••@•••••

  • Saint Luc University Hospital

    RECRUITING

    Brussels, 1200, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St Bartholomew's Hospital

    RECRUITING

    London, EC1A 7BE, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Center Sart-Tilman

    WITHDRAWN

    Liège, 4000, Belgium

  • University Hospital Essen

    RECRUITING

    Essen, Germany

    Contact Email: •••••@•••••

  • University Hospital Ghent

    RECRUITING

    Ghent, 9000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Leuven

    RECRUITING

    Leuven, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Southampton NHS Foundation Trust

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Weill Cornell Medicine - New York - Presbyterian Hospital

    COMPLETED

    New York, New York, 10065, United States

  • Weston Park

    RECRUITING

    Sheffield, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • XCancer Omaha / Urology Cancer Center

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.